{
    "clinical_study": {
        "@rank": "92494", 
        "arm_group": {
            "arm_group_label": "VizAblate treatment", 
            "description": "VizAblate System with subject serving as her own control"
        }, 
        "brief_summary": {
            "textblock": "Study is intended to evaluate the one-year safety and clinical status of patients treated\n      for symptomatic uterine fibroids with the VizAblate Intrauterine-ultrasound guided radio\n      frequency (RF) ablation system.  Particular attention will be directed to recording safety\n      outcomes including incidence of uterine cavity synechiae.  In addition, information on\n      quality of life will be collected.\n\n      Overall study duration (first patient enrolled through last patient exit) will be comprised\n      of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment,\n      and 12 months of follow-up, for a total duration of up to 25 months.  Study duration for an\n      individual patient, once enrolled, will be approximately 1 month for baseline observations\n      and treatment scheduling, and 12 months for follow up after treatment for a total duration\n      of approximately 13 months."
        }, 
        "brief_title": "Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate\u00ae Intrauterine-ultrasound Guided RF Ablation", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Menorrhagia", 
            "Leiomyoma", 
            "Uterine Fibroids", 
            "Uterine Fibroma", 
            "Uterine Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Fibroma", 
                "Leiomyoma", 
                "Myofibroma", 
                "Menorrhagia", 
                "Uterine Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this single-arm study, subjects who receive transcervical intrauterine-ultrasound guided\n      RF ablation of symptomatic uterine fibroids with the VizAblate\u00ae System will be assessed with\n      3D pelvic sonography with contrast, hysteroscopy, and quality of life questionnaires.\n\n      Overall study duration (first patient enrolled through last patient exit) will be comprised\n      of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment,\n      and 12 months of follow-up, for a total duration of up to 25 months.  Study duration for an\n      individual patient, once enrolled, will be approximately 1 month for baseline observations\n      and treatment scheduling, and 12 months for follow up after treatment for a total duration\n      of approximately 13 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  28 years of age or older\n\n          -  Indication for transcervical treatment of uterine fibroids associated with\n             menorrhagia\n\n          -  Willingness to participate in the study, to attend all follow-up visits and undergo\n             all study assessments, and to sign the informed consent form\n\n          -  Presence of submucosal and/or intramural fibroids\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  \u226540 years of age with desire for current or future fertility, unless the estimated\n             risk/benefit ratio has been determined to be more favorable to future pregnancy than\n             standard therapy\n\n          -  Non-sterilized patients < 40 years of age, unless the estimated risk/benefit ratio\n             has been determined to be more favorable to future pregnancy than standard therapy\n\n          -  Active pelvic infection, known or suspected gynecologic malignancy or premalignant\n             condition\n\n          -  Presence of tubal implant for sterilization\n\n          -  Previous pelvic irradiation\n\n          -  Endometrial cavity length, including endocervical canal, < 4.5 cm\n\n          -  Any abnormality of the vagina or uterine cavity that, in the judgment of the\n             investigator obstructs access of the VizAblate handpiece to the endometrial cavity\n\n          -  Presence of cardiac pacemaker or other active implant\n\n          -  Post-menopausal"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "28 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients of specified clinical sites with complaint of symptomatic uterine fibroids."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998854", 
            "org_study_id": "CL03537"
        }, 
        "intervention": {
            "arm_group_label": "VizAblate treatment", 
            "description": "The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids", 
            "intervention_name": "VizAblate System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Menorrhagia", 
            "Leiomyoma", 
            "Uterine Fibroids"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "state": "Cedex", 
                        "zip": "37044"
                    }, 
                    "name": "Le Centre Hospitalier Regional et Universitaire de Tours - H\u00f4pital Bretonneau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "Assistance Publique H\u00f4pitaux de Paris - H\u00f4pital Bic\u00eatre"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate\u00ae Intrauterine-ultrasound Guided RF Ablation", 
        "overall_official": {
            "affiliation": "Gynesonics", 
            "last_name": "David Toub, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean percentage change in treated fibroid perfused volume", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998854"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Fibroid total volume reduction", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The cavity will be as classified per the European Society for Hysteroscopy (ESH)", 
                "measure": "Incidence of Intrauterine adhesiogenesis", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Frequency and type of adverse events occurring on the day of the procedure", 
                "measure": "Procedure Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Day of procedure"
            }, 
            {
                "description": "Frequency and type of adverse events occurring post treatment through 12 months", 
                "measure": "Long-term safety", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Percentage reduction in the Symptom Severity Score sub scale of the Uterine Fibroid Symptom - Quality of Life questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Percentage increase in the Health Related Quality-of-Life (HRQL) sub scale of the Uterine Fibroid Symptom-Quality of Life questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Rate of surgical reintervention for menorrhagia", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Gynesonics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gynesonics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}